|
WO2021076709A1
|
|
Dosages and uses of ornithine phenylacetate for treating hyperammonemia
|
|
WO2020227516A1
|
|
Methods of assessing and treating hepatic encephalopathy
|
|
KR20200024145A
|
|
Method for preparing L-ornithine phenyl acetate
|
|
PH12018500895A1
|
|
Formulation of l-ornithine phenylacetate
|
|
US2017135973A1
|
|
Formulations of l-ornithine phenylacetate
|
|
AU2016353350A1
|
|
Formulation of L-ornithine phenylacetate
|
|
US2018110824A1
|
|
Macrocyclic Modulators of the Ghrelin Receptor
|
|
AU2016325556A1
|
|
Treatment and prevention of neuronal cell loss using L-ornithine in combination with at least one of phenylacetate and phenylbutyrate
|
|
CA2995823A1
|
|
Treatment and prevention of muscle loss using l-ornithine in combination with at least one of phenylacetate and phenylbutyrate
|
|
MX2017013170A
|
|
Formulations of l-ornithine phenylacetate.
|
|
AU2015221466A1
|
|
L-ornithine phenyl acetate and methods of making thereof
|
|
AU2014250643A1
|
|
Treatment of portal hypertension and restoration of liver function using L-ornithine phenylacetate
|
|
KR20140053807A
|
|
Methods of making l-ornithine phenyl acetate
|
|
KR20210019592A
|
|
L-ornithine phenyl acetate and methods of making thereof
|
|
US2009148538A1
|
|
Use of adsorbent carbon microspheres to treat pouchitis
|
|
WO2008021486A1
|
|
Use of adsborbent carbon microspheres (ast-120) to treat gastroesophogeal reflux disease or symptoms thereof
|
|
WO2008021378A1
|
|
Use of adsborbent carbon microspheres to treat intestinal bacterial infections
|
|
WO2007067663A1
|
|
Use of adsorbent carbon microspheres for the treatment of irritable bowel syndrome
|
|
EP2316846A2
|
|
Spatially-defined macrocyclic compounds useful for drug discovery
|
|
EP2210612A2
|
|
Macrocyclic antagonists of the motilin receptor
|
